Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity
Herein, we describe the discovery of a novel immunostimulatory drug conjugate (IMC) that employs TLR7/8 agonists conjugated to a tumor-targeting LIV1 antibody. Targeting TLR7/8 agonists to LIV1-expressing tumors enables localized delivery, thereby minimizing systemic toxicity while promoting inflammation and T cell recruitment within the tumor microenvironment (TME) for enhanced antitumor efficacy. Dual activation of TLR7 and TLR8 within the TME facilitates the recruitment of diverse immune cells and induces a broad spectrum of pro-inflammatory cytokines, effectively reshaping the immunosuppressive TME by upregulating costimulatory molecules. The mechanism of action of the IMC involves tumor recognition via surface antigens and Fcγ-mediated phagocytosis, followed by activation of myeloid cells to efficiently present tumor antigens to T-cells, thereby eliciting antitumor immunity. The designed IMCs demonstrate the ability to activate myeloid cells in the presence of tumor cells, display robust antitumor activity, and are well tolerated in toxicology studies.
Authors
- Yam B. Poudel (ORCID: https://orcid.org/0000-0002-8694-1084)
- Anuradha Gupta (ORCID: https://orcid.org/0000-0002-4211-1441)
- Madhura Deshpande (ORCID: https://orcid.org/0000-0002-9942-4932)
- Shiuhang Yip (ORCID: https://orcid.org/0000-0002-0828-3442)
- Arvind Mathur (ORCID: https://orcid.org/0000-0003-3146-8485)
- Miranda L. Broz
- Mahammed Kaspady (ORCID: https://orcid.org/0000-0003-2238-2006)
- Dauh‐Rurng Wu (ORCID: https://orcid.org/0000-0002-2166-9753)
- Pavel Strop (ORCID: https://orcid.org/0000-0001-8695-577X)
- Emanuela Sega
- Dieter M. Drexler
- Srikanth Kotapati (ORCID: https://orcid.org/0000-0003-2302-5350)
- Sean M. West (ORCID: https://orcid.org/0000-0003-1038-0222)
- Qinqin Cheng (ORCID: https://orcid.org/0000-0003-0138-1944)
- Okechukwu Ukairo (ORCID: https://orcid.org/0000-0002-1785-7663)
- Michael J. Smith (ORCID: https://orcid.org/0000-0003-1478-8081)
- SJ Diong (ORCID: https://orcid.org/0000-0002-4516-8355)
- Lore Florin
- Deborah Law
- Henry Chan (ORCID: https://orcid.org/0000-0001-9565-7408)
- Kumar B. Pabbisetty (ORCID: https://orcid.org/0000-0001-9669-4059)
- Kathryn Que
- Sayumi Yamazoe (ORCID: https://orcid.org/0000-0002-2169-7674)
- Christoph W. Zapf (ORCID: https://orcid.org/0000-0001-5153-5206)
- Ekaterina G. Deyanova (ORCID: https://orcid.org/0000-0002-9663-5590)
- James Kempson (ORCID: https://orcid.org/0000-0002-9540-3886)
- Deepa Pookot
- Shishir Chourey (ORCID: https://orcid.org/0000-0002-2629-9632)
- Stephen M. Carl
- Yvonne Li
- Radha Ramakrishnan (ORCID: https://orcid.org/0000-0002-2356-4402)
- Nicholas Wilson (ORCID: https://orcid.org/0000-0002-2632-704X)
- Matthew Cox (ORCID: https://orcid.org/0000-0002-0172-2895)
- Eugene P. Chekler
- Anandaroop Mukhopadhyay
- Alexander Kozhich
- Rahima Akter
- Scot Liu
- Aram Chang
- Keerthi Sadanala
- Debabrata Bhattasali (ORCID: https://orcid.org/0000-0002-0707-7743)
Institutions
- Bristol-Myers Squibb (Germany) (DE)
- Biocon (Switzerland) (CH)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (India) (IN)
- Biocon (India) (IN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c00264
- Citations
- 4
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 3.19